# Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

> **NCT06405100** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Air Force Military Medical University, China** · enrollment: 81 (estimated)

## Conditions studied

- Minimal Change Disease

## Interventions

- **DRUG:** Supportive care+Prednisone
- **DRUG:** Supportive care+Tacrolimus+Ripertamab
- **DRUG:** Supportive care+Ripertamab

## Key facts

- **NCT ID:** NCT06405100
- **Lead sponsor:** Air Force Military Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06405100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06405100, "Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06405100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*